Dr. Ellen Hartenbach, MD
Claim this profileUniversity of Wisconsin Hospital and Clinics
Studies Skin Cancer
Studies Ovarian Cancer
7 reported clinical trials
15 drugs studied
Area of expertise
1Skin Cancer
Stage IV
Stage III
HER2 positive
2Ovarian Cancer
Stage IV
Stage III
BRCA1
Affiliated Hospitals
Clinical Trials Ellen Hartenbach, MD is currently running
Selinexor Maintenance Therapy
for Endometrial Cancer
The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v 1.1\]) after completing at least 12 weeks of platinum-based therapy. A total of 220 participants will be enrolled in the study and randomized in a 1:1 ratio to maintenance therapy with either selinexor or placebo.
Recruiting1 award Phase 32 criteria
Herceptin Hylecta or Phesgo + Chemotherapy
for Uterine Cancer
This phase II/III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial cancer. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial cancer.
Recruiting1 award Phase 2 & 3
More about Ellen Hartenbach, MD
Clinical Trial Related4 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Ellen Hartenbach, MD has experience with
- Paclitaxel
- Carboplatin
- Oregovomab
- AL3818
- Pegylated Liposomal Doxorubicin (PLD)
- Topotecan
Breakdown of trials Ellen Hartenbach, MD has run
Skin Cancer
Ovarian Cancer
Endometrial Cancer
Gastroesophageal Junction Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ellen Hartenbach, MD specialize in?
Ellen Hartenbach, MD focuses on Skin Cancer and Ovarian Cancer. In particular, much of their work with Skin Cancer has involved Stage IV patients, or patients who are Stage III.
Is Ellen Hartenbach, MD currently recruiting for clinical trials?
Yes, Ellen Hartenbach, MD is currently recruiting for 2 clinical trials in Madison Wisconsin. If you're interested in participating, you should apply.
Are there any treatments that Ellen Hartenbach, MD has studied deeply?
Yes, Ellen Hartenbach, MD has studied treatments such as Paclitaxel, Carboplatin, Oregovomab.
What is the best way to schedule an appointment with Ellen Hartenbach, MD?
Apply for one of the trials that Ellen Hartenbach, MD is conducting.
What is the office address of Ellen Hartenbach, MD?
The office of Ellen Hartenbach, MD is located at: University of Wisconsin Hospital and Clinics, Madison, Wisconsin 53792 United States. This is the address for their practice at the University of Wisconsin Hospital and Clinics.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.